(Corrects headline, first paragraph to remove reference to Eylea)
(Reuters) -Regeneron Pharmaceuticals Inc beat Wall Street estimates for first-quarter profit on Thursday, driven by strong demand for eczema treatment Dupixent.
Excluding items, the company reported a profit of $10.09 per share for the quarter, above analysts’ estimates of $9.56, according to Refinitiv data.
(Reporting by Sriparna Roy and Raghav Mahobe in Bengaluru; Editing by Devika Syamnath)
